Using Alternative Implants for the Surgical Treatment of Hip Fractures (The FAITH Study)
Launched by UNIVERSITY OF MINNESOTA · Sep 26, 2008
Trial Information
Current as of August 27, 2025
Completed
Keywords
ClinConnect Summary
One type of hip fracture, called a femoral neck fracture, involves a break in the narrow part of the femur bone where the head of the femur is joined to the main shaft. The break can be either undisplaced, which involves very little separation at the fracture site, or displaced, in which there is substantial separation. Surgeons agree that the best surgical procedure for an undisplaced fracture is internal fixation, in which a mechanical implant reconnects the two separated segments of bone. For displaced fractures, surgeons usually choose between internal fixation and a hip joint replaceme...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Fracture of femoral neck
- • Operative treatment within 4 days for displaced fractures
- • Operative treatment within 7 days for nondisplaced fractures
- • Ambulatory before the injury
- • Low energy trauma, such as falls from a sitting or standing position
- • No other major trauma
- Exclusion Criteria:
- • Unsuited for both surgical treatments
- • Associated major injuries of the lower extremities
- • Retained hardware around the hip
- • Infection around the hip
- • Bone metabolic disorder (except for osteoporosis)
- • Moderate or severe cognitive impairment
- • Parkinson's disease or dementia
- • Unable to complete the 2-year follow-up
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Greenville, South Carolina, United States
Boston, Massachusetts, United States
Cleveland, Ohio, United States
Dayton, Ohio, United States
Burlington, Massachusetts, United States
San Jose, California, United States
Temple, Texas, United States
Saint Louis, Missouri, United States
Fort Sam Houston, Texas, United States
Columbia, Missouri, United States
Birmingham, Alabama, United States
Indianapolis, Indiana, United States
Irvine, California, United States
Orange, California, United States
Denver, Colorado, United States
Grand Junction, Colorado, United States
Indianapolis, Indiana, United States
Grand Rapids, Michigan, United States
Saginaw, Michigan, United States
Minneapolis, Minnesota, United States
Saint Paul, Minnesota, United States
New Brunswick, New Jersey, United States
Rochester, New York, United States
Asheville, North Carolina, United States
Cincinnati, Ohio, United States
Youngstown, Ohio, United States
Nashville, Tennessee, United States
Lubbock, Texas, United States
San Antonio, Texas, United States
Spokane, Washington, United States
Patients applied
Trial Officials
Marc Swiontkowski, MD
Principal Investigator
University of Minnesota
Mohit Bhandari, MD
Principal Investigator
McMaster University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials